(12) **Translation of European patent specification**

(11) **NO/EP 2488525 B1**

NORWAY

(19) NO

(51) Int Cl.

C07D 487/04 (2006.01)
A61K 31/519 (2006.01)
A61P 31/00 (2006.01)
A61P 31/04 (2006.01)
C07D 403/10 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.10.01
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.04.25
(86)	European Application Nr.	10824203.3
(86)	European Filing Date	2010.10.15
(87)	The European Application's Publication Date	2012.08.22
(30)	Priority	2009.10.16, US, 252478 P 2010.03.16, US, 314287 P 2010.06.24, US, 358201 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Melinta Therapeutics, Inc., 300 George Street, Suite 301, New Haven, CT 06511, US-USA
(72)	Inventor	DUFFY, Erin, M., 349 River Road, Deep River, CT 06417, US-USA BHATTACHARJEE, Ashoke, 461 Cardinal Lane, Cheshire, CT 06410, US-USA O'DOWD, Hardwin, 21 Wormwood Street, Unit 516, Boston, MA 02210, US-USA KANYO, Zoltan, F., 1270 Ridge Road, North Haven, CT 06473, US-USA MARTYNOW, Jacek, G., 7214 Town Ridge, Middletown, CT 06457, US-USA PAIK, Ik-Hyeon, 39 Ives Street, Unit 305, Hamden, CT 06518, US-USA DEVIVO, Marco, 641 Whitney Avenue, Apt. 3B, New Haven, CT 06511, US-USA SCHEIDEMAN, Matthew, H., 702 Quinnipiac Avenue, Unit G, New Haven, CT 06513, US-USA WIMBERLY, Brian, T., 882 Moose Hill Road, Guilford, CT 06437, US-USA WU, Yusheng, 56 Starr Street, New Haven, CT 06511, US-USA SINISHTAJ, Sandra, 468 Marlborough Road, Yonkers, NY 10701, US-USA
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME**

(56) References Cited: WO-A2-2008/082440, US-A- 5 958 930, ROBERT HUDSON ET AL: "Fluorescent 7-Deazapurine

Derivatives from 5-Iodocytosine via a Tandem Cross-Coupling-Annulation Reaction with Terminal Alkynes", SYNLETT, vol. 13, 1 January 2004 (2004-01-01), pages 2400-2402, XP055063664,, ZLATKO JANEBA ET AL.: 'Synthesis and Biological Evaluation of Acyclic 3-[(2-H ydroxyethoxy)methyl] Analogues of Antiviral Furo- and Pyrrolo[2,3-d]pyrimidi ne Nucleosides' J. MED. CHEM. vol. 48, 2005, pages 4690 - 4696, FILLIP WOJCIECHOWSKI ET AL.: 'Peptide Nucleic Acid Containin g a Meta-Substituted Phenylpyrrolocytosine Exhibits a Fluorescence Response and Increased Binding Affinity toward RNA' ORGANIC LETTER vol. 11, no. 21, 29 September 2009, pages 4878 - 4881, SHUN-ICHI KAWAHARA ET AL.: 'Computer-Aided Molecular Design of Hydrogen Bond Equivalents of Nucleobases: Theoretical Study of Substituent Effects on the Hydrogen Bond Energies of Nucleobase Pairs' EUR. J. ORG. CHEM. 2003, pages 2577 - 2585, Adam Sniady ET AL: "Zinc-Catalyzed Cycloisomerizations. Synthesis of Substituted Furans and Furopyrimidine Nucleosides", The Journal of Organic Chemistry, vol. 73, no. 15, 1 August 2008 (2008-08-01), pages 5881-5889, XP055406344, ISSN: 0022-3263, DOI: 10.1021/jo8007995, WO-A2-2009/113828, US-A1- 2002 193 385, R. H. E. HUDSON ET AL: "Nucleobase Modified peptide Nucleic Acid", NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, vol. 22, 2003, pages 1029-1033, XP009169738,, FILLIP WOJCIECHOWSKI ET AL.: 'Exceptional Fluorescence and Hybridization Properties of a Phenylpyrrolocytosine in Petide Nucleic Acid' NUCLEIC ACIDS SYMPOSIUM SERIES 2008, pages 401 - 402, ALEEM GANGJEE ET AL.: 'Synthesis of Classical, Three-Carbon-Bridged 5-Substit uted Furo[2,3-d]pyrimidine and 6-Substituted Pyrrolo[2,3-d]pyrimidine Analog ues as Antifolates' J. MED. CHEM. vol. 47, 2004, pages 6893 - 6901, WO-A1-2004/080466

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. Forbindelse som har formelen:



(Ia),

hvori -G-H-J-alternativet er



hvori hver H og J er uavhengig valgt,
D og E er enkeltbindinger og F er hydrogen,
C-B-A- og -G-H-J er kjemiske rester, hvori
A er valgt fra
(a) en 3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen og svovel, og
(b) en 3-14-leddet mettet, umettet eller aromatisk karbosyklus,
hvori (a) eller (b) eventuelt er substituert med én eller flere R^5-grupper;
G er
(a) en 3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen, oksygen og svovel, eller
(b) en 3-14-leddet mettet, umettet eller aromatisk karbosyklus,
hvori (a) eller (b) eventuelt er substituert med én eller flere R^5-grupper;
H er valgt fra gruppen som består av:
(a) en enkeltbinding;
(b) en 3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen, oksygen og svovel,
(c) en 3-14-leddet mettet, umettet eller aromatisk karbosyklus,
hvori (b) eller (c) eventuelt er substituert med én eller flere R^5-grupper;
(d) -(C_{1-8}-alkyl)-, (e) -(C_{2-8}-alkenyl)-, (f) -(C_{2-8}-alkynyl)-, hvori
i) 0-4 karbonatomer i enhver av (d)-(f) rett ovenfor eventuelt erstattes av en rest valgt fra gruppen som består av -O-, -$S(O)_p$-, -NR^6-, -(C=O)-, -$C(=NR^6)$-, -$S(O)_pNR^6$-, -$NR^6S(O)_p$-, og $NR^6S(O)_pNR^6$-,
ii) enhver av (d)-(f) rett ovenfor eventuelt substitueres med én eller flere R^5-grupper; og
iii) enhver av (d)-(f) rett ovenfor eventuelt substitueres med -(C_{1-8} alkyl)-R^5-grupper;

og (g) -$(CR^6R^6)_t$-,

B er (a) -(C_{1-8}-alkyl)-, (b) -(C_{2-8}-alkenyl)-, (c) -(C_{2-8}-alkynyl)-, eller (d) en enkeltbinding, der

i) 0-4 karbonatomer i enhver av (a)-(c) rett ovenfor eventuelt erstattes av en rest valgt fra gruppen som består av -O-, -$S(O)_p$-, -NR^6-, -(C=O)-, -$C(=NR^6)$-, -$S(O)_pNR^6$- og -$NR^6S(O)_pNR^6$-,

ii) enhver av (a)-(c) rett ovenfor eventuelt substitueres med én eller flere R^5-grupper, og/eller

iii) enhver av (a)-(c) rett ovenfor eventuelt substitueres med -(C_{1-8}-alkyl)-R^5-grupper;

C og J er uavhengig valgt fra gruppen som består av:

(a) hydrogen, (c) F, (d) Cl, (e) Br, (f) I, (g) -CF_3, (h) -CN, (i) -N_3 (j) NO_2,

(k) -$NR^6(CR^6R^6)_tR^8$, (1) -OR^8, (m) -$S(O)_p(CR^6R^6)_tR^8$, (n) -$C(O)(CR^6R^6)_tR^8$,

(o) -$OC(O)(CR^6R^6)_tR^8$, (p) -$SC(O)(CR^6R^6)_tR^8$, (q) -$C(O)O(CR^6R^6)_tR^8$,

(r) -$NR^6C(O)(CR^6R^6)_tR^8$, (s) -$C(O)NR^6(CR^6R^6)_tR^8$, (t) -$C(=NR^6)(CR^6R^6)_tR^8$,

(u) -$C(=NN^6R^6)(CR^6R^6)_tR^8$, (v) -$C(=NNR^6C(O)R^6)(CR^6R^6)_tR^8$, (w) -$C(=NOR^8)(CR^6R^6)_tR^8$,

(x) $NR^6C(O)O(CR^6R^6)_tR^8$, (y) -$OC(O)NR^6(CR^6R^6)_tR^8$, (z) -$NR^6C(O)NR^6(CR^6R^6)_tR^8$,

(aa) $NR^6S(O)_p(CR^6R^6)_tR^8$, (bb) -$S(O)_pNR^6(CR^6R^6)_tR^8$, (cc) -$NR^6S(O)_pNR^6(CR^6R^6)_tR^8$,

(dd) -NR^6R^8, (ee) -$NR^6(CR^6R^6)R^8$, (ff) -OH, (gg) -NR^8R^8, (hh) -OCH_3, (ii) -$S(O)_pR^8$,

(jj) -$NC(O)R^8$, (kk) -$NR^6C(NR^6)NR^6R^8$, (ll) C_{1-8}-alkyl, (mm) C_{2-8}-alkenyl, (nn) C_{2-8}-alkynyl,

(oo) en 3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen, oksygen og svovel,

(pp) en 3-14-leddet, mettet, umettet eller aromatisk karbosyklisk ring,

(qq) -$(CR^6R^6)_tNR^6(CR^6R^6)_tR^8$, (rr) -$N[(CR^6R^6)_tR^8][C=O(CR^6R^6)_tR^8]$,

(ss) -$(CR^6R^6)_tN[(CR^6R^6)_tR^8][(CR^6R^6)_tR^8]$, (tt) -$(CR^6R^6)_tNR^6(C=O)(CR^6R^6)_tR^8$,

(uu) -halogenalkyl, (w) -$C(O)(CR^6)[(CR^6R^6)_tR^8]R^8$, (ww) -$(CR^6R^6)_tC(O)NR^8R^8$,

(xx) -$(CR^6R^6)_tC(O)O(CR^6R^6)_tR^8$, (yy) $NR^6C(O)CR^8R^8R^8$, (zz) -$N[(CR^6R^6)_tR^8]C(O)R^8$, og

(aaa) -$S(O)_pNR^8R^8$;

hvori (ll) til (pp) eventuelt er substituert med én eller flere R^7-grupper;

R^5 er valgt fra (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) -CF_3, (g) -CN, (h) -N_3 (i) -NO_2, (j) -NR^6R^6, (k) -OR^8, (1) -$NR^6(CNR^6)NR^6R^6$, (m) -C_{1-8}-alkyl, (n) -C_{2-8}-alkenyl, (o) -C_{2-8}-alkynyl, (p) -(C_{1-8}-alkyl)-(3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen, oksygen og svovel), (q) -(C_{1-8}-alkyl)-(3-14-leddet mettet, umettet eller aromatisk karbosyklisk ring), (r) -halogenalkyl, (s) -SR^6, (t) -(3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen, oksygen og svovel, og (u) -3-14-leddet mettet, umettet eller aromatisk karbosyklisk ring; alternativt tas to R^5-grupper sammen for å danne en karbosyklisk ring

hvori (m) til og med (r) og (t) til og med (u) er eventuelt substituert med ett eller flere R^8;

R^6 er valgt fra (a) hydrogen, (b) -C_{1-8}-alkyl eller alternativt tas to R^6-grupper sammen for å danne en karbosyklisk ring, (c) -halogenalkyl, (d) -3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen, oksygen og svovel og (e) -3-14-leddet mettet, umettet eller aromatisk karbosyklisk ring;

hvori (b) til og med (e) eventuelt er substituert med ett eller flere R^8;

R^7 er valgt fra (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) -CF_3, (g) -CN, (h) -N_3 (i) -NO_2, (j) -NR^6R^6, (k) -OR^6, (1) -$NR^6(CNR^6)NR^6R^6$, (m) -C_{1-8}-alkyl, (n) -C_{2-8}-alkenyl, (o) -C_{2-8}-alkynyl, (p) -(C_{1-8}-alkyl)-(3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen, oksygen og svovel), (q) -(C_{1-8}-alkyl)-(3-14-leddet mettet, umettet eller aromatisk karbosyklisk ring), (r) -halogenalkyl, (s) -NR^6R^8, (t) -OR^8, (u) -$(CR^6R^6)_tNR^6R^8$, (v) -$CR^6R^8R^8$, (w) -SR^6, (x) -(3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen, oksygen og svovel, (y) -3-14-leddet mettet, umettet eller aromatisk karbosyklisk ring; (z) -$(CR^6R^6)_tC(O)NR^8R^8$, (aa) -$S(O)_pR^8$, (bb)-$NR^6C(O)NR^6R^6$, (cc) $NR^6C(O)R^6$, og (dd) -$C(=NR^6)NR^6R^6$;

hvori (m) til og med (q) og (x) til og med (y) er eventuelt substituert med én eller flere R^9;

R^8 er valgt fra (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) -CF_3, (g) -CN, (h) -N_3 (i) -NO_2, (j) -NR^6R^9, (k) -OR^9, (1) -$NR^6(CNR^6)NR^6R^6$, (m) -C_{1-8}-alkyl, (n) -C_{2-8}-alkenyl, (o) -C_{2-8}-alkynyl, (p) -(C_{1-8}-alkyl)-(3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen, oksygen og svovel), (q) -(C_{1-8}-alkyl)-(3-14-leddet mettet, umettet eller aromatisk karbosyklisk ring), (r) 3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen, oksygen og svovel, (s) -3-14-leddet mettet, umettet eller aromatisk karbosyklisk ring, (t) -halogenalkyl, (u) -$C(O)(CR^6R^6)_tR^9$, (v) -SR^6, (w) -$OC(O)(CR^6R^6)_tR^9$, (x) -$NR^6C(O)NR^6R^9$, (y) -$NR^6C(O)R^9$, (z) -$NR^6(CNR^9)(NR^6R^6)$, (aa) -$ONR^6(CNR^6)NR^6R^6$, (bb) -$C(=NR^9)NR^6R^6$, (cc) -$S(O)_pR^9$, (dd) -$(CR^6R^6)_tC(O)NR^6R^9$, (ee) -$(CR^6R^6)_tOR^9$, og (ff) -$(CR^6R^6)_tNR^6R^9$;

hvori (m) til og med (s) er eventuelt substituert med én eller flere R^9;

R^9 er valgt fra (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) -CF_3, (g) -CN, (h) -N_3 (i) -NO_2, (j) -NR^6R^{10}, (k) -OR^6, (1) -$NR^6(CNR^6)NR^6R^6$, (m) -$C(O)(CR^6R^6)_tNR^6R^6$, (n) -C_{1-8}-alkyl, (o)-C_{2-8}-alkenyl, (p) -C_{2-8}-alkynyl, (q) -3-14-leddet, mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt blant gruppen som

består av nitrogen, oksygen, og svovel, (r) -3-14-leddet, mettet, umettet eller aromatisk karbosyklisk ring, (s)-halogenalkyl, (t) $-(CR^6R^6)_tOR^6$, (u) $-O(CR^6R^6)_tNR^6R^{10}$, (v) $-C(O)R^6$, (w) $-SR^6$, (x) $-C(O)OR^{10}$, (y) $-S(O)_pR^6$, (z) $-(C_{1-8}$ alkyl)-(3-14-leddet, mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt blant gruppen som består av nitrogen, oksygen, og svovel), (aa) $-(C_{1-8}$-alkyl)-(3-14-leddet, mettet, umettet eller aromatisk karbosyklisk ring), (bb)-$O(CR^6R^6)_tOR^6$, (cc) $-C(=NR^6)NR^6R^6$, (dd) $-ONR^6R^6$, (ee) $-NR^6C(O)NR^6R^6$, (ff)-$O(CR^6R^6)_tOR^6$, (gg) $-NR^6C(O)R^6$, og (hh) $-(CR^6R^6)_tNR^6R^{10}$;

hvori (n) til og med (r) og (t) til og med (aa) eventuelt er substituert med én eller flere R^{10};

R^{10} er valgt fra (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) $-CF_3$, (g) -CN, (h) $-N_3$, (i) $-NO_2$, (j) $-NR^6R^6$, (k) $-OR^6$, (1) $-NR^6(CNR^6)NR^6R^6$, (m) $-C(O)(CR^6R^6)_tNR^6R^6$, (n) $-C_{1-8}$-alkyl, (o)-C_{2-8}-alkenyl, (p) $-C_{2-8}$-alkynyl, (q) -3-14-leddet, mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt blant gruppen som består av nitrogen, oksygen, og svovel, (r) -3-14-leddet, mettet, umettet eller aromatisk karbosyklisk ring, (s)-halogenalkyl, (t) $-(CR^6R^6)_tOR^6$, (u) $-O(CR^6R^6)_tNR^6R^{10}$, (v) $-C(O)R^6$, (w) $-SR^6$, (x) $-C(O)OR^6$, (y) $-S(O)_pR^6$, (z) $-(C_{1-8}$-alkyl)-(3-14-leddet, mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt blant gruppen som består av nitrogen, oksygen, og svovel), (aa) $-(C_{1-8}$-alkyl)-(3-14-leddet, mettet, umettet eller aromatisk karbosyklisk ring), (bb) $-O(CR^6R^6)_tOR^6$, (cc) $-C(=NR^6)NR^6R^6$, (dd) $-ONR^6R^6$, (ee) $-NR^6C(O)NR^6R^6$, (ff) $-O(CR^6R^6)_tOR^6$, (gg) $-NR^6C(O)R^6$, og (hh) $-(CR^6R^6)_tNR^6R^6$;

p er 0, 1 eller 2, og

t er 1, 2 eller 3,

eller et farmasøytisk akseptabelt salt, ester eller tautomer derav.

2. Forbindelsen ifølge krav 1, hvori

A er valgt fra

(a) en 3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen og svovel, og

(b) en 3-14-leddet mettet, umettet eller aromatisk karbosyklisk ring,

hvori (a) eller (b) eventuelt er substituert med én eller flere R^5-grupper;

B er valgt fra (a) $-(C_{1-8}$-alkyl)-, (b) $-(C_{2-8}$-alkenyl)-, og (c) $-(C_{2-8}$-alkynyl)-, hvori

i) 0-4 karbonatomer i enhver av (a)-(c) rett ovenfor eventuelt erstattes av en rest valgt fra gruppen som består av -O-, $-S(O)_p$-, $-NR^6$-, -(C=O)-, $-C(=NR^6)$-, $-S(O)_pNR^6$-, og $NR^6S(O)_pNR^6$-,

ii) enhver av (a)-(c) rett ovenfor eventuelt substitueres med én eller flere R^5-grupper, og

iii) enhver av (a)-(c) rett ovenfor eventuelt substitueres med $-(C_{1-8}$-alkyl)-R^5-grupper, og

C er valgt fra (a) NH_2, (b) -NHC(=NH)NH_2 og (c) hydrogen,
eller et farmasøytisk akseptabelt salt, ester eller tautomer derav.

3. Forbindelsen ifølge krav 2, hvori
A er valgt fra azepanyl, syklobutyl, syklopentyl, sykloheksyl, sykloheptyl, fenyl, pyridyl, sykloheksenyl, sykloheksadienyl, dihydropyridyl, tetrahydropyridyl, azetidinyl, pyrrolidinyl, piperidinyl og piperidenyl,
hvori enhver av A rett ovenfor eventuelt substitueres med én eller flere R^5-grupper;
B er -(C_{1-8} alkyl)-, hvori
i) 0-4 karbonatomer i (a) rett ovenfor eventuelt erstattes av en rest valgt fra gruppen som består av -O-, -$S(O)_p$-, -NR^6-, -(C=O)-,-$S(O)_pNR^6$-, og -$NR^6S(O)_pNR^6$-,
ii) (a) rett ovenfor eventuelt substitueres med én eller flere R^5-grupper, og
iii) (a) rett ovenfor eventuelt substitueres med -(C_{1-8}-alkyl)-R^5-grupper; og
C er valgt fra (a) NH_2, (b) -NHC(=NH)NH_2 og (c) hydrogen, fortrinnsvis hvori C-B-A- er valgt fra gruppen som består av:





eller et farmasøytisk akseptabelt salt, ester eller tautomer derav.

4. Forbindelsen ifølge krav 1, hvori R^5 er valgt fra (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) $-CF_3$, (g) -CN, (h) $-N_3$ (i) $-NO_2$, (j) $-NH_2$, (k) $-OR^6$, (1) $-NHC(=NH)NH_2$, (m)-C_{1-8}-alkyl, (n) -C_{2-8}-alkenyl, (o) -C_{2-8}-alkynyl, (p) -(C_{1-8}-alkyl) -(3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen, oksygen og svovel), (q) - (C_{1-8}-alkyl)-(3-14-leddet mettet, umettet eller aromatisk karbosyklisk ring), (r) -halogenalkyl, (s) $-SR^6$, (t) -3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen, oksygen og svovel og (u) -3-14-leddet mettet, umettet eller aromatisk karbosyklisk ring; alternativt tas to R^5-grupper sammen for å danne en karbosyklisk ring, eller hvori R^6 er valgt fra

(a) hydrogen, (b) -C_{1-8}-alkyl eller alternativt tas to R^6-grupper sammen for å danne en karbosyklisk ring, (c) -halogenalkyl , (d) -3-14-leddet mettet, umettet eller aromatisk heterosyklisk ring som inneholder ett eller flere heteroatomer valgt fra gruppen som består av nitrogen, oksygen og svovel, og (e) -3-14-leddet mettet, umettet eller aromatisk karbosyklisk ring; eller et farmasøytisk akseptabelt salt, ester eller tautomer derav.

5. Forbindelsen ifølge krav 1, hvori G er valgt fra azepanyl, syklobutyl, syklopentyl, sykloheksyl, sykloheptyl, fenyl, pyridyl, sykloheksenyl, sykloheksadienyl, dihydropyridyl, furanyl, tetrahydrofuranyl, tetrahydropyridyl, azetidinyl, pyrrolidinyl, piperidinyl og piperidenyl, og fortrinnsvis hvori -G-H-J er valgt fra:



og

eller et farmasøytisk akseptabelt salt, ester eller tautomer derav.

6. Forbindelsen ifølge krav 5, hvori hver G-H-J er valgt blant:












SCF3
NH2


SCHF2
NH2


SCH2F
NH2


SCH3
NH2


S(O)nCF3
NH2


S(O)nCHF2
NH2


S(O)nCH2F
NH2


S(O)nCH3
NH2


OH
NH2


NHR5
NH2


SCH3
NH2


S(O)nCH3
NH2

5


OH
NH2


NHR5
NH2


SCH3
NH2


S(O)nCH3
NH2


O
NH2


O
NH2


O
N
NH2


CN
NH2


H
N
O
S
O
NH2















, hvori n er 0, 1, eller 2,

videre hvori R^5 er som definert i krav 5,
eller et farmasøytisk akseptabelt salt, ester eller tautomer derav.

7. Forbindelsen ifølge én av forbindelsene i tabellen nedenfor eller et farmasøytisk akseptabelt salt, ester eller tautomer derav:

Forb. nr.	Struktur
179	
180	

184	
192	
193	
195	
196	
197	
198	

200	
201	
203	
204	
206	
216	

217	
218	
219	
220	

221	
224	
225	
226	
227	

228	
229	
230	
231	
232	

233	
234	
235	
236	

237	
240	
241	
245	

250	
253	
254	
258	
261	

262	
263	
264	
272	
279	

280	
288	
292	
296	
306	
309	

310	
318	
333	
507	
508	

511	
559	
560	
561	
611	

612	
620	
623	
629	
633	
634	
637	

644	
645	
655	
665	
666	

677	
678	
697	
711	
725	

726	
727	
728	
755	

756	
757	
758	
759	

760	
761	
767	
768	

769	
770	
775	

786	
787	
796	
797	

801	
802	
803	

804	
805	
806	
807	
823	

830	
831	
836	
837	

838	
839	
840	

841	
842	
843	

844	
845	
846	
851	

852	
853	
854	
855	

856	
857	
860	

861	
862	
863	

864	
865	
866	
867	

871	
872	
874	
875	

876	
877	
878	

879	
880	
892	
893	

894	
895	
897	

898	
899	
907	

910	
911	
914	

915	
918	
922	

933	
934	
935	

936	
937	
940	
943	

944	
945	
946	
947	
948	

949	
951	
957	

958	
959	
960	

961	
962	
963	

964	
966	
967	

968	
969	
970	

971	
978	
979	

981	
982	
983	

984	
985	
986	

987	
988	
989	

994	
995	
996	

997	
998	
999	

1000	
1001	
1002	

1003	
1004	
1009	

1010	
1011	
1015	
1017	

1018	
1019	
1020	
1021	

1022	
1023	
1027	
1029	

1034	
1035	
1036	
1037	

1038	
1039	
1040	
1043	

1044	
1045	
1047	
1048	

1049	
1050	
1051	
1052	

1053	
1054	
1057	
1060	

1061	
1062	
1063	

1064	
1065	
1066	
1067	

1068	
1069	
1074	

1075	
1076	
1077	
1079	

1080	
1081	
1087	
1088	

1090	
1091	
1092	

1093	
1094	
1099	
1100	

1101	
1102	
1103	
1104	
1105	

1106	
1107	
1110	
1111	
1113	

1114	
1115	
1116	

1117	
1119	
1120	
1121	
1122	

1123	
1124	
1125	

1126	
1127	
1128	
1129	

1130	
1131	
1132	
1136	
1137	

1138	
1139	
1141	
1142	
1143	
1144	

1148	
1150	
1151	
1152	
1154	

1157	
1158	
1159	
1160	

1161	
1162	
1163	
1164	

1165	
1166	
1167	
1168	

1169	
1170	
1171	

1172	
1173	
1174	

1175	
1176	
1177	

1178	
1179	
1180	
1181	

1182	
1183	
1184	
1185	

1186	
1187	
1188	

1190	
1191	
1194	
1195	

1196	
1199	
1200	
1201	

1202	
1203	
1204	
1205	

1206	
1207	
1208	
1210	

1211	
1214	
1215	
1216	

1217	
1218	
1219	

1220	
1221	
1222	
1223	

1224	
1225	
1226	

1227	
1228	
1229	
1230	

1232	
1233	
1241	
1243	

1245	
1246	
1247	
1248	
1249	

1250	
1252	
1253	
1255	

1256	
1257	
1259	
1260	

1261	
1262	
1263	
1264	

1266	
1267	
1268	
1272	

1273	
1274	
1275	
1276	

1277	
1279	
1280	
1281	

1284	
1285	
1286	
1290	

1292	
1293	
1301	
1306	
1307	

1309	
1310	
1316	
1324	

1325	
1326	
1327	
1328	

1329	
1330	
1334	
1335	
1336	

1342	
1343	
1344	
1349	

1350	
1351	
1352	

1359	
1360	
1361	

1365	
1366	
1367	

1371	
1372	
1373	

1374	
1380	
1381	

1390	
1391	
1392	
1393	

1397	
1399	
1400	

1404	
1405	
1406	

1410	
1411	
1412	
1413	

1414	
1415	
1416	
1417	

1418	
1422	
1423	
1428	

1431	
1432	
1433	
1434	

1435	
1436	
1437	
1438	

1439	
1440	
1443	
1444	

1446	
1447	
1448	
1451	

1452	
1453	
1455	
1456	

1457	
1458	
1459	
1460	

1462	
1463	
2000a	
2001a	

2002a	
2003a	
2004a	

2005a	
2006a	
2007a	
2008a	

2009a	
2010a	
2011a	

2012a	
2013a	
2014a	
2015a	

2016a	
2017a	
2018a	
2019a	
2020a	

2021a	
2022a	
2023a	
2024a	

2025a	
2026a	
2027a	
2028a	

2029a	
2030a	
2031a	

2032a	
2033a	
2034a	
2035a	

2036a	
2037a	
2038a	
2039a	

2040a	
2041a	
2042a	
2043a	

2044a	
2045a	
2046a	

2047a	
2048a	
2049a	

2050a	
2051a	
2052a	

2053a	
2054a	
2055a	

2056a	
2057a	
2058a	
2059a	

2060a	
2061a	
2062a	

2063a	
2064a	
2065a	

2066a	
2067a	
2068a	

2069a	
2070a	
2071a	

2072a	
2073a	
2074a	

2075a	
2076a	
2077a	

2078a	
2079a	
2080a	

2081a	
2082a	
2083a	

2084a	
2085a	
2086a	

2087a	
2088a	
2089a	

2090a	
2091a	
2092a	

2093a	
2094a	
2095a	

2096a	
2097a	

8. Forbindelse ifølge krav 1, valgt som



eller et farmasøytisk akseptabelt salt, ester eller tautomer derav.

9. Farmasøytisk sammensetning som omfatter en forbindelse ifølge ett av kravene 1-8, eller et farmasøytisk akseptabelt salt, ester eller tautomer derav, og en farmasøytisk akseptabel bærer.

10. Forbindelse ifølge ett av kravene 1-8, eller et farmasøytisk akseptabelt salt, ester eller tautomer derav, for anvendelse ved behandling, forebygging eller reduksjon av

risikoen for en mikrobiell infeksjon hos et menneske eller dyr, hvori den mikrobielle infeksjonen fortrinnsvis er valgt fra gruppen som består av:
en hudinfeksjon, en Gram-positiv infeksjon, en Gram-negativ infeksjon, nosokomial lungebetennelse, omgivelseservervet lungebetennelse, post-viral lungebetennelse, sykehuservervet lungebetennelse/ventilatorforbundet lungebetennelse, en luftveisinfeksjon så som kronisk luftveisinfeksjon (CRTI), akutt bekkeninfeksjon, en komplisert hud og hudstrukturinfeksjon, en hud- og bløtvevsinfeksjon (SSTI) inkludert ukompliserte hud- og bløtvevsinfeksjoner (uSSTI-er) og kompliserte hud- og bløtvevsinfeksjoner, en abdominal infeksjon, en komplisert intra-abdominal infeksjon, en urinveisinfeksjon, bakteriemi, septisemi, endokarditt, en atrio-ventrikulær shuntinfeksjon, en vaskulær tilgangsinfeksjon, meningitt, kirurgisk profylakse, en peritoneal infeksjon, en beininfeksjon,
en leddinfeksjon, en meticillinresistent *Staphylococcus aureus*-infeksjon, en vankomycinresistent *Enterococci*-infeksjon, en linezolidresistent organismeinfeksjon, en Bacillus anthracis-infeksjon, en Francisella tularensis-infeksjon, en Yersinia pestis-infeksjon og tuberkulose.

11. Forbindelsen for anvendelse ifølge krav 10, hvori forbindelsen, eller et farmasøytisk akseptabelt salt, ester eller tautomer derav administreres optisk, oftalmalt, nasalt, oralt, parenteralt, topisk eller intravenøst.

12. Medisinsk anordning som inneholder en forbindelse ifølge ett av kravene 1-8, eller et farmasøytisk akseptabelt salt, ester eller tautomer derav, hvori anordningen fortrinnsvis er en stent.